NCT07163234 Safety of the IPERF Femoral Arterial Cannula in Patients Undergoing Planned Cardiac Surgery With Extracorporeal Circulation Via Femoral Approach
| NCT ID | NCT07163234 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IPERF SAS |
| Condition | Cardiac Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-02-11 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2026-02-11 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a first-in-human, prospective, single-arm, phase I clinical study evaluating the safety of the iPerf femoral arterial cannula in patients undergoing planned cardiac surgery requiring extracorporeal circulation (ECC) via a femoral approach for up to 6 hours. The iPerf device is a dual-lumen arterial cannula designed to provide systemic and lower limb perfusion during ECC, with the goal of reducing the risk of acute limb ischemia. The study will be conducted at a single center in France and will include 15 adult patients. Primary outcomes focus on procedure-related and late adverse events up to 30 days post-surgery. Secondary objectives include assessment of ischemic events, tissue oxygen saturation, and surgeon satisfaction with device handling. The study aims to demonstrate feasibility and safety of the iPerf cannula as an innovative solution for lower limb perfusion during femoral artery cannulation.
Eligibility Criteria
Inclusion criteria * Patient aged 18 years or older * Patient able to understand the study procedures, provide written informed consent, and comply with study procedures * Patients with planned cardiac surgery requiring the use of an extracorporeal circulation via a femoral approach for a maximum of 6 hours. * Patient affiliated to the social security system Exclusion criteria * Patient weighting less than 45 kg * Patient weighting more than 130 kg * Patient with common femoral artery diameter less or equal to 6 mm * Patient with a stenosis of the aorta, iliac artery, or femoral artery reducing their diameter of more than 50% * Patient with previous vascular or endovascular surgery of the iliac or femoral arteries * Patient participating in another interventional study * Patients with known arterial dissection * Patient who is pregnant at the time of enrollment * Patients under judicial protection, guardianship or curatorship or subjects deprived of their liberty by judicial or administrative decision
Contact & Investigator
Pierre Mordant, Surgeon
STUDY DIRECTOR
Frequently Asked Questions
Who can join the NCT07163234 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07163234 currently recruiting?
Yes, NCT07163234 is actively recruiting participants. Contact the research team at dogufa76@gmail.com for enrollment information.
Where is the NCT07163234 trial being conducted?
This trial is being conducted at Massy, France, Massy, France.
Who is sponsoring the NCT07163234 clinical trial?
NCT07163234 is sponsored by IPERF SAS. The principal investigator is Pierre Mordant, Surgeon. The trial plans to enroll 15 participants.